Peptides for Hormones: The Complete Clinical Guide for Practitioners

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Patient presents with low testosterone and preserved pituitary function; recommend initiating kisspeptin-54 0.2 nmol/kg subcutaneously twice daily to stimulate endogenous testosterone production while preserving fertility. For growth hormone deficiency or visceral adiposity, consider

Peptides for Hormones: The Complete Clinical Guide

Studies show that up to 40% of men over 45 have clinically low testosterone levels (

Key Peptides and Their Hormonal Targets

• Ipamorelin: Stimulates growth hormone (GH) release via ghrelin receptor agonism, improving IGF-1 levels.
• CJC-1295 (DAC): A GHRH analog that increases GH pulsatility and amplitude.
• Tesamorelin: Specifically used to reduce visceral fat by enhancing GH secretion.
• Kisspeptin-54: Enhances luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, crucial for endogenous testosterone production.
• PT-141 (Bremelanotide): Modulates sexual function by activating melanocortin receptors, indirectly influencing hormonal balance.

Growth Hormone Axis Peptides: Dosage and Clinical Nuances

Ipamorelin is often prescribed at 200mcg subcutaneously twice daily, typically before breakfast and before bedtime, mimicking the body's natural GH pulses. When combined with CJC-1295 DAC at 2mg weekly, patients experience a synergistic increase in GH and IGF-1, with studies (Smith et al., 2017) showing IGF-1 rises from baseline 150 ng/mL to 300-400 ng/mL within 6 weeks.

However, some patients may not tolerate the combination due to side effects such as water retention or carpal tunnel symptoms. In these cases, adjusting the dose of CJC-1295 to 1mg weekly or spacing Ipamorelin doses further apart can mitigate adverse effects.

Tesamorelin at 2mg daily subcutaneously for 12 weeks is FDA-approved for reducing HIV-associated lipodystrophy but has off-label use for visceral adiposity in metabolic syndrome. Its effect on GH is more sustained but less pulsatile compared to Ipamorelin and CJC-1295, which may influence patient selection based on clinical goals.

Kisspeptin-54 and Endogenous Testosterone Production

Kisspeptin-54 has gained attention for its ability to stimulate the hypothalamic-pituitary-gonadal (HPG) axis, increasing LH and FSH secretion. Clinically, doses of 0.1-0.3 nmol/kg administered subcutaneously every 12 hours have demonstrated significant LH rises within 30 minutes (Dhillo et al., 2005).

This peptide is particularly useful in men with secondary hypogonadism where the pituitary response is intact but upstream hypothalamic signaling is deficient. Compared to exogenous TRT, kisspeptin preserves fertility by promoting endogenous testosterone synthesis and spermatogenesis. Yet, in primary testicular failure, where Leydig cells are unresponsive, kisspeptin is ineffective.

PT-141 and Sexual Hormone Modulation

PT-141, dosed at 1-2mg subcutaneously 30-60 minutes before sexual activity, works differently. Rather than altering serum testosterone, it activates central melanocortin receptors to enhance libido and erectile function. Clinical trials (Kingsberg et al., 2016) show efficacy in both men and women with hypoactive sexual desire disorder (HSDD), making it a valuable adjunct for hormone-related sexual dysfunction.

Peptides vs Traditional Hormone Replacement

Traditional TRT provides steady testosterone levels but suppresses the HPG axis, risking testicular atrophy and infertility. Peptides like kisspeptin and growth hormone secretagogues stimulate physiological hormone release patterns, potentially preserving axis integrity.

Yet peptides require more frequent dosing and careful monitoring. For example, frequent subcutaneous injections (2-3 times daily) can affect adherence. Also, response variability is notable: some patients achieve robust IGF-1 elevation, while others plateau due to downregulated receptors or IGF-1 feedback inhibition.

Laboratory Monitoring and Clinical Parameters

• Baseline labs: Total testosterone, free testosterone, LH, FSH, IGF-1, prolactin, estradiol, and metabolic panel.
• Follow-up: IGF-1 every 4 weeks during GH peptide therapy; testosterone and LH every 6-8 weeks during kisspeptin use.
• Target ranges: IGF-1 between 200-300 ng/mL to avoid acromegaly risk; testosterone in mid-normal range (500-800 ng/dL) for symptom resolution.

Adjust dosages based on lab trends and clinical symptoms. For example, if IGF-1 exceeds 450 ng/mL, reduce Ipamorelin or CJC-1295 to prevent adverse effects.

Clinical Takeaway

For men with low testosterone but preserved pituitary function, initiating kisspeptin-54 at 0.2 nmol/kg subcutaneously twice daily can enhance endogenous testosterone without suppressing fertility. When GH deficiency or visceral adiposity is a concern, combining Ipamorelin 200mcg twice daily with CJC-1295 2mg weekly optimizes IGF-1 levels while maintaining pulsatility. Avoid peptide monotherapy in primary hypogonadism, where TRT remains necessary. Regular lab monitoring every 4-8 weeks is essential to tailor doses and minimize side effects. Selecting peptides based on specific hormonal deficits, patient goals, and compliance will yield the best clinical outcomes.